Zai Lab Net Income 2016-2022 | ZLAB

Zai Lab net income from 2016 to 2022. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Zai Lab Annual Net Income
(Millions of US $)
2021 $-704
2020 $-269
2019 $-195
2018 $-139
2017 $-50
2016 $-38
2015 $-18
Zai Lab Quarterly Net Income
(Millions of US $)
2022-03-31 $-82
2021-12-31 $-212
2021-09-30 $-96
2021-06-30 $-163
2021-03-31 $-233
2020-12-31 $-77
2020-09-30 $-64
2020-06-30
2020-03-31 $-48
2019-12-31
2019-09-30
2019-06-30
2018-12-31
2017-12-31
2017-06-30
2016-12-31
2015-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $2.937B $0.144B
Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $165.194B 10.05
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.361B 16.35
Biohaven Pharmaceutical Holding (BHVN) United States $10.098B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.208B 0.00
Emergent Biosolutions (EBS) United States $1.617B 6.92
Arcus Biosciences (RCUS) United States $1.305B 33.09
Myovant Sciences (MYOV) United Kingdom $0.956B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.500B 0.00
Zymeworks (ZYME) Canada $0.368B 0.00
Gelesis Holdings (GLS) United States $0.349B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.108B 22.10
SQZ Biotechnologies (SQZ) United States $0.097B 0.00